Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement



Status:Completed
Conditions:Arthritis, Osteoarthritis (OA)
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - 90
Updated:4/21/2016
Start Date:January 2014
End Date:December 2015

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Randomized Controlled Trial of Tranexamic Acid and ε-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty

Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss
following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic
acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee
arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and
EACA provide similar blood decreasing effects following TKA or whether one drug provides a
superior effect over the other in reducing patients' blood loss.


Inclusion Criteria:

- Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee
replacement surgery

Exclusion Criteria:

- Non-English speaking individuals

- Individuals with a history of deep vein thrombosis or pulmonary embolism within one
year

- Individuals with a history of coagulopathy

- Heart stent within one year

- Pre-operative autologous blood donation

- Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis

- Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant
treatment within five days prior to surgery

- Pre-operative creatinine greater than 1.5mg/dL
We found this trial at
1
site
Miller Orthopedic Specialists
Council Bluffs, Iowa 51503
?
mi
from
Council Bluffs, IA
Click here to add this to my saved trials